Small Molecules

all catalysts(0)

nothing on the calendar yet

News(10)

• MindMaze trims Relief staff, Aardvark cuts workforce amid Prader-Willi troubles
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 22h ago
• Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
  Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.
  fiercebiotech · 1d ago
• With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
  AI is quickly becoming a central force in drug development, from powering pharma engines to permanently rewiring the capital markets.
  biospace · 2d ago
• BMS picks Texas for new $2.3B manufacturing campus
  Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
  biospace · 3d ago
• Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
  The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
  biopharma_dive · 3d ago
• AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
  AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women…
  fiercebiotech · 4d ago
• Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program
  Arpeggio Biosciences’ eight-year song has come to an end, as the transcriptome biotech’s CEO admitted the that company’s Nrf2 program had begun to “unravel.”
  fiercebiotech · 4d ago
• LifeMine raises $263M in mission to improve organ transplant aftercare
  Patients who receive an organ transplant must take difficult immuno-suppressive medicines for the rest of their lives. LifeMine Therapeutics wants to offer a safer alternative.
  biospace · 8d ago
• BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
  Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperw…
  fiercebiotech · 28d ago
• Biotech startup funding gap widens despite rebound in VC investment
  Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.
  biopharma_dive · 1mo ago